It is self-explanatory that most patients, who were excluded from these pembrolizumab registration trials due to the results of EGFR test, carried exon 19 deletion or L858R substitution in the tumor tissue, while only a minority if any LC cases were represented by rare EGFR mutations. Here, EGFR is linked to neoplasm.